Beishujie® (Procaterol Hydrochloride Inhalation Solution), approved for marketing

Entered into in-depth cooperation with Keli Pharmaceuticals, a subsidiary of Hanmi Group, on Oseltamivir phosphate dry suspension in the agreed channel

An asset purchase agreement (the "Agreement") was signed with Sol-Gel Technologies, Ltd. ("Sol-Gel", Nasdaq stock Code: SLGL) to acquire all relevant assets of dermatology product TWYNEO® in the mainland of China, Hong Kong, Macau, Taiwan and Israel (the "Territory") from Sol-Gel

Beimei's self-developed product, Bilastine oral solution marketing application accepted

Oselavir®, PRESOMID®and LANCOVUL®successfully listedin 2023 National Reimbursement Drug List

PRESOMID®,“Beizesi”®,LANCOVUL®successfully won inthe ninth roundof National Pharmaceutical VBP

LANCOVUL®(Lacosamide Oral Solution) approved for marketing

Completedthe C round financing of tens of million, invested by Jiangsu Jinqiao Private FundManagement, Nanshan SEIInvestment and PanglinGroup

The first self-developed product, “Beizesi”®(Atomoxetine Hydrochloride Oral Solution), approved for marketing